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Abstract 
BACKGROUND: HCV infection and its complications are among the leading public health challenges; the 
emergence of drug-resistant variants are expected to be a major problem. A novel combinatorial small interfering 
RNA (siRNA) could be a novel triple therapy that could be suitable for genotype 4. Although HCV is a hepatotropic 
virus, there is reliable evidence about its replication in peripheral blood mononuclear cells (PBMC) of chronically 
infected patients; these cells act as an extra-hepatic reservoir for viral recurrence and persistence. The patients 
with HCV-RNA in PBMC showed a significantly lower response to therapy that supports to be one of the factors 
influencing therapeutic response. Almost all regions of HCV show potential for siRNA target with relative 
efficiencies of individual siRNA sequences. 
AIM: This study aims to test the efficacy of siRNA against HCV-4 replication in PBMC in vitro, to introduce an 
alternative therapeutic option for HCV-4 suitable to eradicate it from both hepatic and extra-hepatic reservoirs. 
METHODS: Efficacy of synthesised siRNA molecule that targets 5
/
UTR of domain IIIC within IRES of HCV RNA 
to eradicate HCV intra-PBMC in vitro was tested and compared with IFN/RBV in vitro, by using both qRT-PCR 
and western blot. Sixty genotype-4 chronic HCV patients who are naïve for any HCV treatment were enrolled and 
tested for the presence of HCV intra-PBMC using qRT-PCR before and after siRNA treatment in vitro.  
RESULTS: Real-time PCR analysis showed a significant reduction of HCV RNA levels after 24hr post-HCV-
positive-PBMCs treatment by siRNA with cell vitality reached up to 98%. Besides a complete inhibition of NS5A 
viral protein expression, that is functionally essential for viral assembly, replication and egress. 
CONCLUSION: So, Targeting HCV infection using RNA interference technology might be a reliable therapeutic 
option for chronic HCV patients with HCV minus strand within PBMCs. 
 
 
 
Introduction 
 
Hepatitis C virus (HCV) infection is a global 
blood-borne disease that affects almost 3% of the 
world population with morbidity and mortality that is 
second to HIV among the emerging infections [1]. 
Egypt has been reported as the highest in HCV 
prevalence worldwide, that ranged from 6% to exceed 
40% among region and demographic groups with 11-
14% of the population chronically infected with the 
virus [2]. The infection may get worse to cirrhosis with 
the subsequent development of complications 
including hepatocellular carcinoma [3], [4]. 
HCV is a positive-sense single-stranded RNA 
virus, classified as the sole member of the genus 
Hepacivirus in the family Flaviviridae. The HCV RNA 
genome is roughly 9.6 kb long with an open Reading 
Frame (ORF) that encode a vast viral polyprotein of 
around 3,01 thousand amino acids [4]. Viral 
translation is mediated through the internal ribosome 
entry site (IRES) found within the 5’ untranslated 
region (5’UTR) which comprise of ~341 bp long that is 
profoundly conserved even between various HCV 
isolates. The 5’UTR does not encode for functional 
protein and contains the IRES that initiate viral 
polyprotein translation in a cap-independent manner 
[5]. The IRES is basic for translational as it 
independently binds to the 40S ribosomal subunit and 
guides the ribosome to the initiation codon of the HCV 
mRNA with a specific end goal to facilitate its 
translation in a cap-independent manner. It contains 
four profoundly organised stem-looped domains that 
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named I-IV which facilitate HCV RNA translation. 
Domain I is not essential for IRES activity but rather 
essential for HCV replication, IRES in domains II-IV 
play a role in viral genetic replication in a cap-
independent manner while Domain III contains 
subdomains that are critical for the binding of 40S 
ribosomal subunit [6]. Translation of HCV mediated by 
a profoundly conserved internal ribosomal Entry site 
(IRES) within the 5'UTR making it a significant focus 
for new medication development [5]. 
Despite hepatotropic nature of HCV, many 
studies proved that PBMC represents another 
extrahepatic reservoir where HCV can replicate, not 
only that, but it may also be the real culprit in viral 
recurrence after liver transplantation [7]. The 
substantial goal of viral treatment is to attain a 
sustained virological response (SVR) that is defined 
as undetectable HCV-RNA in peripheral blood 
determined 24 weeks after the end of treatment 
(ETR). Nonresponders (NR) to therapy are sometimes 
obstinate to retreatment and do not necessarily 
benefit from escalating treatment dose [8].  
Despite the great success of the current 
therapies, there are many reported concerns that may 
increase the demand for new therapy and diagnostic 
approach to cover it [4], for example; Human Biliverdin 
reductase (HBVr) reported to be upregulated in many 
studies upon Direct-acting antivirals (DAAs) therapy, 
HBVr usually elevated at mean of 52 days after first 
DAA dose and reported to cause ten DAA-therapy 
discontinuations [9]. These patients cannot make a 
benefit from DAAs, so alternative options are urgently 
necessary, out of this alternative is RNAi that 
represent an effective silencing approach for 
molecular therapeutics through a particular 
succession RNA degradation procedure to diminish 
infection or replication of its invaders [5]. 
siRNA is promising silencing mechanism, 
vector-based or synthetic siRNAs directed against 5' 
UTR, NS3, NS5B, NS4B and core represented 
significant specific ability in reducing both viral 
infection and replication. The 5
/
UTR of HCV-IRES has 
also been targeted by siRNA resulted in inhibition of 
HCV by more than 80% at a concentration of 2.5 nM. 
Moreover, consensus siRNAs against 5
/
UTR 
diminished viral replication level in vitro on infected 
Huh-7 cell-line [10]. While the dominant part of HCV-
siRNAs is integral to the positive strand, a lessening in 
both strands replication has been reported [11]. It is 
conceivable that targeting the positive strand leads to 
a decline in negative strands synthesis [12]. 
Interferon (IFN) pathway can be initiated by 
dsRNAs, so it was important to address whether HCV-
particular siRNAs could trigger IFN pathway. It was 
exhibited that hindrance of viral replication by HCV 
RNAi in vitro was not related to an up-regulation of 
IFN-stimulated genes. Targeting HCV by siRNAs were 
better at diminishing HCV-RNA levels than an 
oscillating dose of IFN-α [11].  
  All these possibilities motivate us to test the 
efficacy of specific synthetic-siRNA on clearance of 
HCV from PBMCs of chronic HCV-infected patients 
aiming to get a new therapeutic recommendation for 
inconvenient DAAs therapy patients, non-responders 
or relapse’s patients. In addition to scavenging viral 
infection from PBMCs that act as a real culprit in HCV 
relapses after liver transplantation. 
 
 
Patients and Methods 
 
Patients and Samples collection  
Total of sixty patients was enrolled in this 
study; all were naïve and newly diagnosed HCV 
patients, from National Hepatology and Tropical 
Medicine Research Institute (NHTMRI) Cairo, Egypt. 
All patients were pre-diagnosed HCV antibody 
positive by ELISA technique. HCV detected in serum 
and PBMC for all samples. Ethical committee 
approval was taken from National Hepatology and 
Tropical Medicine Research Institute in addition to a 
signed consent form from each patient. Patient’s 
inclusion criteria were; first, they should be treatment 
naïve patients, then they should not have any other 
neurological disorders or undergo conservative 
treatment, also not to be co-infected by any hepatic 
viral infection than HCV that was detected by the 
presence of its antibodies (Ab) in serum. About 12 mL 
blood was withdrawn from each patient on heparin. 
 
siRNA Choice  
siRNA targeting domain IIIC within IRES was 
chosen that showed 100% alignment with HCV 
sequences in the gene bank (database), in addition to 
its ability to align specifically against domain IIIC 
within IRES. This siRNA was specially synthesised 
and ordered from thermo-scientific U.S.A (cat# K-
005000-G1-01, E-007500 -01), to be HPLC purified 
and sterilised using ultra-filtration methods to assure 
removal of any materials that might interfere with 
transfection or might be lethal to cells. 
 
Optimising siRNA Transfection Procedure  
Since there is a great variation in the capacity 
of transfection according to each cell type, so the 
transfection procedure must be determined and 
adjusted for each cell line before transfection. Also, it 
is well known that PBMCs is hard to transfect cells. 
Therefore, the GAPDH siRNA (Thermo, USA) was 
used to optimise: a) optimal cell plating density; b) 
optimal amount of siRNA to be transfected; and c) 
either to transfect it in serum-free or serum-containing 
medium (FCS) and determine optimal serum 
concentration. 
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Self-delivery Accell™-siRNAs were 
synthesised by Dharmacon® that allows effective 
delivery in wide-ranging cell lines including primary 
cells. Ficoll-hypaque density gradient technique was 
used to isolate PBMC from the blood. PBMC was 
washed at least four times with PBS, re-suspended in 
Accell delivery media®, and counted; then 1 × 10
6
 
cells were used for detection of presence of HCV and 
0.6 ×10
6
 cells/well were plated in 48 well-plate for 
testing efficacy of different siRNA concentrations (50-
100-200 µM) on silencing HCV replication and 
compare its effect with IFN/RBV in separate wells 
were concomitantly treated with 110 IU/ml IFN 
plus100 µM Ribavirin in vitro [13]. Total RNA was 
harvested at different times post-siRNA transfection 
using Viral RNA extraction kit (QIAamp-viral RNA mini 
kit) from QIAGEN according to the manufacturer's 
manual. Also, control for HCV-siRNA was used that 
was Human GAPDH siRNA in addition to positive and 
negative (non-targeting NTC) control for each. 
 
Determination of HCV in Patient’s Sera 
Two hundred (µL) serum were used for RNA 
extraction by viral RNA extraction kit (QIAamp-viral 
RNA mini kit- QIAGEN-USA) consistent with the 
manufacturer's manual. 200 ng of RNA utilised to 
detect virus C using one-step RT-PCR kit (QIAGEN, 
USA) and used as stated by the manufacturer's 
protocol, and then the PCR amplicon was 
photographed on 2% agarose gel. 
 
HCV Genotyping  
Genotyping was done using the VERSANT HCV 
genotype 2.0 Assay (LiPA - Bayer).  
 
Uncovering HCV Strands in Patient’s 
PBMC  
 
Qualitative analysis 
Cellular RNA was extracted from counted 
uncultured PBMC, collected from HCV serum positive 
patients, using Viral RNA extraction kit (QIAamp-viral 
RNA mini kit- QIAGEN, USA) consistent with the 
manufacturer's manual. HCV strands were detected 
by RT-PCR; briefly, 200 ng of extracted RNA was 
reversely transcribed to cDNA in 50 µL mixture PCR 
beads (GE healthcare life science, USA) and 25 
pmoles antisense primer 
5'GGTGCACGGTCTACGAGACCTC3' for a positive 
strand or 5'AACTACTGTCTTCACGCAGAA3' for a 
negative one. 50 µL was the first round PCR volume, 
using 50 pmoles from each primer and 
5'TGCTCATGGTGCACGGTCTA3'. Then the second 
round uses 20% of this volume for its amplification 
with the internal pair of primers 
5CGCAGAAAGCGTCTAGCCAT3 in addition to 
5ACTCGGCTAGCAGTCTCGCG3. The thermal cycler 
conditions were the same as the first round, then PCR 
amplicon was analysed on 2% agarose gel 
electrophoresis and documented. 
 
Quantitative analysis 
HCV quantitation was performed on a Piko-
Real-Time PCR System (Thermo-Scientific) using 
sensifast SYBR kit (Bioline) according to the 
manufacturer procedure. 
 
In vitro treatment of infected PBMC by siT 
and IFN/RBV 
Patients proved to be infected with HCV in 
both serum and PBMCs were enrolled in this step. 
PBMCs were separated using ficoll, washed 4 times 
with PBS to avoid any attached viral particles on cell 
membrane, then resuspended in Accell delivery 
media® For each patient, cells were plated on a 48-
well plate at a concentration of 0.6 × 10
6
/mL, and 
cultured at 37˚C, 5% CO2 for 72 hr in absence or 
presence different siRNA concentrations, siNTC, 
GAPDH siRNA and IFN/RBV separately (triplicate for 
each treatment). Cultured cells without any treatment 
were used as a control. Cells were harvested, washed 
4 times with PBS, and subjected to total cellular RNA 
extraction. Total RNA extracted from cultured PBMCs 
was reverse transcribed and amplified using the same 
assay described previously for both qualitative and 
quantitative measurement [14]. 
 
Western blot analysis of HCV NS5A 
antigens in PBMC with and without siRNA 
Cell lysates of PBMC either with or without 
siRNA treatment were subjected to SDS-PAGE. Then 
washed three times, after that membrane was 
incubated with diluted peroxidase-labelled anti-human 
IgG/IgM antibody mixture at 1:5000 in phosphate 
buffer saline (PBS) 3 g/L for previously treated strips 
with the anti-NS5A (Novocastra Laboratories, UK) for 
at least two hr at room temperature. Then Visualize of 
the immune complexes on the nitrocellulose 
membranes by promoting the strips with 0.01 mol/L 
PBS (pH 7.4) that contain 40 mg 3,3',5,5 
tetramethylbenzidine and 100 μl of 30 ml/L hydrogen 
peroxide (Immunopure TMB substrate Kit, Rockford, 
USA). 
 
Statistical Analysis 
All experiments were performed in triplicates 
on three independent cultures. Data were shown in 
means ± SD. P < 0.05 was considered statistically 
significant. 
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Results 
 
Clinical Aspects of HCV patients 
Patients showed a significant difference 
(P<0.001) in liver function test ALT, AST, liver 
synthetic function assays; prothrombin and albumin 
(P<0.0001) and total leukocyte count (P=0.0002), on 
the other hand Age, BMI, gender, and total bilirubin 
showed no significant difference between normal and 
chronic HCV infected patients Table (1). 
Table 1: Clinical data of chronic-HCV patients’ vs healthy 
control 
Variable Chronic HCV 
patients 
(mean ± SD) 
Healthy persons 
(mean ± SD) 
P value 
Age 49 ± 10 47±8 0.674 (NS) 
BMI (Kg/m
2
) 26.8 ± 5 26.2±5 0.7464 (NS) 
Gender 
Male 
Female 
 
22 (55%) 
18 (45%) 
 
5 (50%) 
5 (50%) 
 
0.5719 (NS) 
0.5687 (NS) 
Platelet count (10
3
/µL) 216 ± 68 265±120 0.1006 (NS) 
ALT (IU/L) 68.1 ± 41.7 13±6 0.0003 (S) 
AST (IU/L) 52.3 ± 32.6 12±8 0.0006 (S) 
Bilirubin Total (mg/dl) 0.43 ± 0.16 0.39±0.19 0.1087 (NS) 
Bilirubin Direct (mg/dl) 0.85 ± 0.37 0.29±0.16 0.086 (NS) 
Prothrombin concentration % 69.9 ± 19.3 103±4.7 <0.0001 (S) 
Albumin (g/dl) 3.28 ± 0.6 4.7±0.8 <0.0001 (S) 
Total leukocyte count (10
3
/µL) 6.08 ± 2.18 3.0±1.5 =0.0002 (S) 
Serum HCV viral load 
<500,000 IU/ml 
≥500,000 IU/ml 
 
25 (62.5%) 
15 (37.5%) 
 
0 
0 
 
PBMC viral load 
PBMC + HCV 
PBMC -HCV 
 
19 (47.5%) 
21 (52.5%) 
 
0 
0 
 
Fibrosis level 
F (n: 0/1/2/3/4) 
 
16/14/9/1 
 
0/0/0/0 
 
NS= no significant difference; S = significant difference. 
 
HCV RNA detectability in Patient’s Serum 
and PBMC 
All the 60 patients were HCV RNA positive in 
serum but only 19 out of them (31.7%) showed 
detectable HCV -RNA in PBMC using RT-PCR for 
HCV strands, from clinical data observations, 
17(89.5%) out of these 19 PBMC positive HCV patient 
show non-responder state to PEG-IFN and 11(64.7%) 
showed non-response to sovaldi therapy at week 12. 
 
Results of optimisation of siRNA 
concentration and delivery method in vitro 
To assess the potentiality and efficacy of 
siRNA in Accell delivery media, optimisation of the 
various parameters carried out using GAPDH siRNA 
as a positive internal control. The results represented 
a significant silencing of GAPDH mRNA expression in 
transfected PBMCs when Accell delivery reagent was 
used (p < 0.05) (Figure 1). But there was no observed 
inhibition when lipofectamine nor electroporation was 
used compared to using Accell delivery with no siRNA 
as a negative control. 
Two other transfection reagents were tested 
for transfection optimisation. Accell delivery media 
showed a significant knockdown of GAPDH compared 
to Lipofectamine and Electroporation; (A); p < 0.05. 
Values expressed as relative expression value (REV) 
with mean ± SD, n = 19. 
 
Figure 1: Effect of different delivery methods on GAPDH expression 
 
Results of in vitro inhibition of HCV 
replication by siRNA in PBMC 
Current study demonstrates that the 
introduction of siRNA targeting domain IIIC within 
5’UTR IRES site into PBMC, that previously confirmed 
to be infected by HCV using quantitative PCR assay, 
caused a dramatic sharp decrease of HCV RNA by 
more than 94% compared to non-treated cells using 
qRT-PCR (Table 2), also NS5A protein expression 
levels detected by western blot assay was completely 
inhibited (Figure 3). was also noticed that the effect of 
siRNA on HCV replication and life-cycle occurs very 
early after 24 hours post siRNA transfection with 
variable treatment concentrations (Figure 2).  
Table 2: The HCV RNA levels (%*) in HCV-infected PBMCs 
inhibited by siRNA for 72 h 
 Doses of siRNA (nM) 
10 50 100 200 
Untreated  100 ± 11.47 100 ± 5478 100 ± 14474 100 ± 3446 
siGAPDH 96 ± 19.47 86 ± 9.24 80 ± 8.96 76 ± 11407 
siNTC 92 ± 8.25 92 ± 14.63 111 ± 16.28 115 ± 5.13 
siT 29 ± 12.50
a
 18 ± 5.50
a
 6 ± 1.11
a,b
 8 ± 2.83
a,b
 
IFN/RBV (110 IU/ml IFN plus100 µM 
Ribavirin) 
57±11.8
a
 
RBV (100 µM Ribavirin) 8 ± 2.7
a
 
*data Presented as viral load (mean ± SD); 
a
 P˂0.01, as compared with untreated control; 
b
P˂0.01, as compared with the 10nM group; 
c
P˂0.01, as compared with the 50nM group. 
 
siRNA were applied to HCV-infected PBMCs 
cell-culture to assess the effects of siRNA on the HCV 
replication. Infected PBMCs that were untreated and 
transfected non-targeting (scrambled) siRNA (siNTC) 
served as negative controls while PBMCs that were 
untreated and transfected with GAPDH siRNA served 
as positive controls, Figure 3 and Table 2 illustrate 
viral RNA levels and protein expression for both 
transfected and control PBMCs, as quantitated by 
qPCR at 72 h after transfection. siRNA was 
significantly able to suppress HCV replication at 100 
nM compared with untreated PBMCs (P ˂ 0.01).  
 Youssef et al. Silencing HCV Replication in Its Reservoir 
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Figure 2: Concentration optimisation using GAPDH siRNA. All 
values were expressed as relative expression value (REV) with 
mean ± SD, n = 9 
 
The result of the quantitative PCR of samples 
after these in vitro treatments shows significant viral 
reduction with siT compared to IFN/RBV (P = 0.001). 
As shown in Table 2, SiT decreased the viral load by 
mean ± SD 94.0 ± 1.11% while the combination 
therapy decreased it by mean 57 ± 11.8% and finally 
ribavirin alone decreases it by mean 8 ± 2.7% only 
that later complied with in-vivo response results for 
same patients of IFN/RBV and DAAs therapies.  
NS5A levels were significantly decreased 
after 24 hr. of the transfection of 100 nM of SiT (Fig. 
3). And maximum inhibition levels were observed on 
72 hr. post transfection (mean silencing 94.0 ± 
1.11%). Also, there are no significant inhibition levels- 
for HCV in cells transfected with either the NTC siRNA 
nor those with GAPDH siRNA- was detected. 
 
Figure 3: Composite picture for Western blot for HCV-NS5A 
compared to intracellular GAPDH 
 
Upper row showed HCV-NS5A expression in 
different transfection for PBMC positive HCV cells 
after 24hr post-treatment. Lower row showed the 
GAPDH expression in same transfected cells. 
 
Results of SiRNA cytotoxicity detection 
To detect possible cytotoxic effects that may 
be induced by the siRNA, both trypan-blue exclusion 
method and MTT assay were performed. The cell 
viabilities reached up to 98% (Table 3) for both cells 
transfected by siRNA or for cells grown in Accell 
delivery media (transfection media). Thus, neither the 
transfection media (on another way transfection 
process) nor selected siRNA in the current study 
induced toxicity against PBMCs cells. 
  
Table 3: Cell viability (%*) of PBMCs exposed to either siRNA 
for 72 h or IFN/RBV 
 Doses of siRNA (nM) 
10 50 100 200 
Untreated  100 ± 4.47 100 ± 3.72 100 ± 2.46 100 ± 1.16 
siGAPDH 96 ± 19.47 86 ± 9.24 80 ± 8.96 76 ± 11407 
siNTC 100 ± 9.86 100 ± 5.72 108 ± 4.28 105 ± 5.2 
siT 102 ± 3.50 108 ± 6.50 116 ± 11.11 118 ±1 2.53 
IFN/RBV (110 IU/ml IFN plus100 µM 
Ribavirin) 
57±11.8
a
 
RBV (100 µM Ribavirin) 68±18.2
a
 
* data Presented as viral load (mean ± SD) siNTC= siRNA non targeting pool control. 
 
 
Discussion 
 
In the current study, 60 genotypes 4 chronic 
HCV infected patients were enrolled. They are naïve 
for HCV treatment, HCV RNA was detected in PBMCs 
of 19 patients out of 60 (about 31.7%), and the 
remainder show no HCV in its PBMCs, similarly this 
finding complies with our result that was published 
2014 [14] that represent presence of HCV intra-PBMC 
in 10 out of 25 HCV infected patients that represent 
40% of total study population. 
Viral translation is mediated through IRES site 
found within the 5
/
UTR that consists of ~341 bp in 
length with highly conserved sequence even between 
different HCV isolates. IRES can initiate viral 
polyprotein translation in a cap-independent manner 
via independently binds to the 40S ribosomal subunit 
and directs the ribosome to the initiation codon of 
mRNA of HCV to expedite translation in a cap-
independent manner and it is a vital target for the 
development of new antiviral compounds [15]. 
It is well known that viruses, particularly 
retroviruses and HCV, are notoriously prone to the 
high rate of errors during their replication process, and 
continuously undergoes mutation and mostly produce 
mutated viral proteins to escape immune-system 
defence mechanisms. These mutations may also 
escape attacking by various siRNAs [16]. The protein-
coding sequence of the HCV genome that was 
targeted in the study by McCaffrey et al., 2002 varies 
considerably among different HCV genotypes, and 
even among strains of the same genotype [17]. Also, 
the high error rate of the non-proofreading HCV RNA-
dependent RNA polymerase greatly showed that was 
called “siRNA escape mutants” which have silent 
mutations in the protein-coding sequence [18]. In 
contrast, the 5'UTR especially IRES IIIC, that was 
selected as a target in the current study, is almost 
identical among the known strains of HCV[7]. 
Moreover, structural fetters on the 5'UTR, regarding 
its ability to direct internal ribosome entry and 
translation of viral proteins, would not riddance 
escape mutations [19]. 
For this reason, the IRES domains within 
5'UTR of the HCV genome appears to be an ideal 
target for siRNA in clinical applications. Not all 5'UTR-
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directed siRNAs have the same efficacy; there are 
many siRNA were detected based on the consensus 
sequences of Egyptian HCV 5’UTR. In this study siT 
was chosen that showed 100% alignment with HCV 
sequences in the gene bank (database) and also can 
align in 5’UTR specifically against domain IIIC within 
IRES in silico then we validate this hypothesis in the 
wet lab. 
In the current study, we were able to 
demonstrate that the introduction of SiT targeting 
domain IIIC within IRES in 5’UTR into PBMC that 
previously confirmed its infection by HCV using 
quantitative PCR assay, caused a dramatic sharp 
decrease of HCV RNA by more than 94% compared 
to non-treated cells, HCV RNA levels decreased 25-
fold (P = 0.0005) in Huh-7 cells too after transfection 
with siRNA (data not shown), in addition to modulation 
of NS5A viral protein expression. It was noticed that 
the effect of siRNA on HCV replication and life-cycle 
occurs very early after 24 hours post siRNA 
transfection. Our data is in agreement with both 
McCaffrey et al., 2002 [17] who showed in his study 
that, HCV NS5B RNA polymerase gene fragment, 
which was transiently co-transfected with siRNA into 
mouse liver by hydrodynamic injection, was cleaved 
after treatment with specific siRNA [17]. Our data are 
also consistent with those of Randall et al., 2003 who 
demonstrated that siRNA could target and cleaves the 
HCV 5'UTR efficiently and specifically. More 
importantly, Randall and his associates showed that 
the cleavage of HCV-RNA not only suppressed viral 
protein synthesis but also blocked the replication of 
sub-genomic viral RNA [20] that was supported by our 
data from PBMCs too. 
Up to our Knowledge, it’s the first time for a 
comparative study between the effect of either 
ribavirin alone or with combination with IFN at 
recommended dose against 100 µM siRNA as optimal 
dose and we clearly observe the superior effect of 
siRNA over other treatment on PBMC in vitro, as the 
same pattern, Table 2 showed the superiority of siT 
that reached 94% viral clearance while the 
combination therapy decreased it by 57% and finally 
ribavirin decreased it by 8% only, the finding support 
siRNA efficiency on HCV silencing either in hepatic 
cell or extra-hepatic reservoir like PBMCs, Also it was 
the first time to test efficacy of siRNA to eradicate 
HCV replication on PBMCs that are hard to transfect 
cells acts as HCV reservoir4 
As a safe and efficient way of delivery of 
siRNAs to cells that can suppress HCV replication in 
all infected cells in vivo have not been discovered yet, 
chemically specially modified synthetic siRNA might 
easily be made and delivered into cells on their own. 
In our study we compared three different ways of 
transfection and we conclude that Accell siRNA 
delivery method® is specially modified for use without 
a transfection reagent and works at a higher 
concentration than classical siRNA with minimal 
disruption of the expression profile and approved to 
transfect hard to transfect cells like PBMCs with no 
off-target effect (Figure 1).  
Results showed that the siT that we selected, 
siT- (nt 59–79 from the 5'UTR beside nt 109–129 from 
the HCV core area), successfully inhibit HCV 
replication in PBMC culture without affecting 
housekeeping genes (Figure 3), it was clearly 
observed safety profile of siT on PBMCs in addition to 
cell vitality that exceeded 98% using trypan blue 
exclusion method and cytotoxicity MTT assay, thus 
confirming earlier reports on siRNA and suggesting 
the potential therapeutic value of siRNA in HCV type-
4.  
To confirm our result and data both Q-PCR of 
viral RNA, western blot for NS5A protein were 
performed to assess the effect of siT at 24 hr on such 
protein expression. NS5A may be an RNA binding 
protein because of its ability to bind to 3’UTR of the 
plus and minus HCV RNA strands with a key 
modulator role of host cell function and activity, 
especially IFN response of the host cell, despite 
siRNA showed superior efficacy in modulating NS5A 
gene expression in this study, results need more 
validation by comparing its efficacy to DAAs targeting 
the same NS5A like Declatasvir® and Elbasvir®.  
Our preliminary data showed that siT 
efficiently suppresses HCV replication in PBMC in 
vitro. The result of this study overcomes our result of 
another study previously published in 2014; antisense 
SODN1 for inhibition of HCV in both PBMC and 
hepatoma cells because of failure of antisense to 
eradicate HCV within PBMCs compared to hepatoma 
cells [14]. Besides over-coming IFN+RBV too making 
it promising molecule for either non-responders or 
relapses’ patients beside those non-suitable for 
current therapies. 
Our data suggest that siRNAs targeting 5'UTR 
can induce an anti-HCV response in cell culture of 
PBMC harbouring the virus. Therefore, it represents a 
future therapy that could eradicate viral RNA from 
either hepatic cells or PBMCs, and consequently, it 
can potentially cure patients with HCV by eradicating 
it from its reservoir. The efficiency of siT in inhibiting 
HCV replication in PBMCs potentially suggests that 
this RNA-targeting approach might support and 
provide an effective therapeutic option for HCV 
infection especially for those hard to treated patients. 
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